Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: a longitudinal study in a first episode psychosis cohort

Objective: metabolic syndrome is a health-threatening condition suffered by approximately one third of schizophrenia patients and largely attributed to antipsychotic medication. Previous evidence reports a common genetic background of psychotic and metabolic disorders. In this study, we aimed to ass...

Descripción completa

Detalles Bibliográficos
Autores: Segura, Àlex G., Martínez-Pinteño, Albert, Gassó, Patricia, Rodríguez, Natalia, Bioque, Miquel, Cuesta, Manuel J., González-Peñas, Javier, García-Rizo, Clemente, Lobo, Antonio, González-Pinto, Ana, García-Alcón, Alicia, Roldán, Alexandra, Vieta, Eduard, Castro-Fornieles, Josefina, Mané Santacana, Anna, Saiz-Ruiz, Jerónimo, Bernardo, Miquel, Mas, Sergi
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/55083
Acceso en línea:http://hdl.handle.net/10230/55083
http://dx.doi.org/10.1016/j.schres.2022.05.021
Access Level:acceso abierto
Palabra clave:Metabolic syndrome
Polygenic risk score
Psychotic disorders
id ES_0bd126e2854dd0c5addee2a641b6b2df
oai_identifier_str oai:recercat.cat:10230/55083
network_acronym_str ES
network_name_str España
repository_id_str
spelling Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: a longitudinal study in a first episode psychosis cohortSegura, Àlex G.Martínez-Pinteño, AlbertGassó, PatriciaRodríguez, NataliaBioque, MiquelCuesta, Manuel J.González-Peñas, JavierGarcía-Rizo, ClementeLobo, AntonioGonzález-Pinto, AnaGarcía-Alcón, AliciaRoldán, AlexandraVieta, EduardCastro-Fornieles, JosefinaMané Santacana, AnnaSaiz-Ruiz, JerónimoBernardo, MiquelMas, SergiMetabolic syndromePolygenic risk scorePsychotic disordersObjective: metabolic syndrome is a health-threatening condition suffered by approximately one third of schizophrenia patients and largely attributed to antipsychotic medication. Previous evidence reports a common genetic background of psychotic and metabolic disorders. In this study, we aimed to assess the role of polygenic risk scores (PRSs) on the progression of the metabolic profile in a first-episode psychosis (FEP) cohort. Method: of the 231 FEP individuals included in the study, 192-220 participants were included in basal analysis and 118-179 in longitudinal 6-month models. Eleven psychopathologic and metabolic PRSs were constructed. Basal and longitudinal PRSs association with metabolic measurements was assessed by statistical analyses. Results: no major association of psychopathological PRSs with the metabolic progression was found. However, high risk individuals for depression and cholesterol-related PRSs reported a higher increase of cholesterol levels during the follow-up (FDR ≤ 0.023 for all analyses). Their effect was comparable to other well-established pharmacological and environmental risk factors (explaining at least 1.2% of total variance). Conclusion: our findings provide new evidence of the effects of metabolic genetic risk on the development of metabolic dysregulation. The future establishment of genetic profiling tools in clinical procedures could enable practitioners to better personalize antipsychotic treatment selection and dosage.Elsevier202220222022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/55083http://dx.doi.org/10.1016/j.schres.2022.05.021reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)Inglés0920-9964/© 2022 Segura ÀG, Martínez-Pinteño A, Gassó P, Rodríguez N, Bioque M, Cuesta MJ, et al. Published by Elsevier B.V. This article is available under the Creative Commons CC-BY-NC-ND http://creativecommons.org/licenses/by-nc-nd/4.0/http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10230/550832026-05-29T05:05:01Z
dc.title.none.fl_str_mv Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: a longitudinal study in a first episode psychosis cohort
title Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: a longitudinal study in a first episode psychosis cohort
spellingShingle Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: a longitudinal study in a first episode psychosis cohort
Segura, Àlex G.
Metabolic syndrome
Polygenic risk score
Psychotic disorders
title_short Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: a longitudinal study in a first episode psychosis cohort
title_full Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: a longitudinal study in a first episode psychosis cohort
title_fullStr Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: a longitudinal study in a first episode psychosis cohort
title_full_unstemmed Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: a longitudinal study in a first episode psychosis cohort
title_sort Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: a longitudinal study in a first episode psychosis cohort
dc.creator.none.fl_str_mv Segura, Àlex G.
Martínez-Pinteño, Albert
Gassó, Patricia
Rodríguez, Natalia
Bioque, Miquel
Cuesta, Manuel J.
González-Peñas, Javier
García-Rizo, Clemente
Lobo, Antonio
González-Pinto, Ana
García-Alcón, Alicia
Roldán, Alexandra
Vieta, Eduard
Castro-Fornieles, Josefina
Mané Santacana, Anna
Saiz-Ruiz, Jerónimo
Bernardo, Miquel
Mas, Sergi
author Segura, Àlex G.
author_facet Segura, Àlex G.
Martínez-Pinteño, Albert
Gassó, Patricia
Rodríguez, Natalia
Bioque, Miquel
Cuesta, Manuel J.
González-Peñas, Javier
García-Rizo, Clemente
Lobo, Antonio
González-Pinto, Ana
García-Alcón, Alicia
Roldán, Alexandra
Vieta, Eduard
Castro-Fornieles, Josefina
Mané Santacana, Anna
Saiz-Ruiz, Jerónimo
Bernardo, Miquel
Mas, Sergi
author_role author
author2 Martínez-Pinteño, Albert
Gassó, Patricia
Rodríguez, Natalia
Bioque, Miquel
Cuesta, Manuel J.
González-Peñas, Javier
García-Rizo, Clemente
Lobo, Antonio
González-Pinto, Ana
García-Alcón, Alicia
Roldán, Alexandra
Vieta, Eduard
Castro-Fornieles, Josefina
Mané Santacana, Anna
Saiz-Ruiz, Jerónimo
Bernardo, Miquel
Mas, Sergi
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Metabolic syndrome
Polygenic risk score
Psychotic disorders
topic Metabolic syndrome
Polygenic risk score
Psychotic disorders
description Objective: metabolic syndrome is a health-threatening condition suffered by approximately one third of schizophrenia patients and largely attributed to antipsychotic medication. Previous evidence reports a common genetic background of psychotic and metabolic disorders. In this study, we aimed to assess the role of polygenic risk scores (PRSs) on the progression of the metabolic profile in a first-episode psychosis (FEP) cohort. Method: of the 231 FEP individuals included in the study, 192-220 participants were included in basal analysis and 118-179 in longitudinal 6-month models. Eleven psychopathologic and metabolic PRSs were constructed. Basal and longitudinal PRSs association with metabolic measurements was assessed by statistical analyses. Results: no major association of psychopathological PRSs with the metabolic progression was found. However, high risk individuals for depression and cholesterol-related PRSs reported a higher increase of cholesterol levels during the follow-up (FDR ≤ 0.023 for all analyses). Their effect was comparable to other well-established pharmacological and environmental risk factors (explaining at least 1.2% of total variance). Conclusion: our findings provide new evidence of the effects of metabolic genetic risk on the development of metabolic dysregulation. The future establishment of genetic profiling tools in clinical procedures could enable practitioners to better personalize antipsychotic treatment selection and dosage.
publishDate 2022
dc.date.none.fl_str_mv 2022
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/55083
http://dx.doi.org/10.1016/j.schres.2022.05.021
url http://hdl.handle.net/10230/55083
http://dx.doi.org/10.1016/j.schres.2022.05.021
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403249184866304
score 15,811543

Similares en LA Referencia